Sanofi Starting US Cialis OTC Actual Use Study Soon While Tamiflu Switch Progress Delayed
French Pharma Reports €1.33Bn Q1 Consumer Health Sales Helped By Price Increases
After 118.2% cough/cold sales growth leads 17% overall consumer business growth, Sanofi points to still stronger days ahead while keeping the business under the same roof with its pharmaceutical and vaccine divisions.
You may also be interested in...
Potential hurdles FDA put in front of Sanofi’s planned tadalafil switch could be sign for agency’s expectations for moving other Rx ingredients to OTC. Sanofi announced its planned actual use trial to support OTC tadalafil use was “placed on clinical hold due to matters surrounding the protocol design.”
Sanofi Consumer Healthcare is to operate as a standalone unit in a move which is being viewed as a prelude to a potential spin-off. High profile prescription-to-OTC switches are a priority for the revamped business.
Sanofi consumer health chief Alan Main says with the US the largest OTC drug market, a successful switch for Tamiflu, marketed in the US by Roche subsidiary Genentech, would support the firm's global strategy for expanding cough and cold remedy sales.